Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Net product sales consist of the following:



	Three Months Ended September 30,				Nine Months Ended September 30,
Net Product Sales in the United States	2018		2017		2018		2017
EYLEA^®	$	1,021,782	$	953,279	$	2,997,829	$	2,727,132
ARCALYST^®	3,706		4,088		11,950		12,613
	$	1,025,488	$	957,367	$	3,009,779	$	2,739,745

The collaboration revenue we earned from Sanofi is detailed below:



	Three Months Ended September 30,						Nine Months Ended September 30,
Sanofi Collaboration Revenue	2018			2017			2018			2017
Antibody:
Reimbursement of Regeneron research and development expenses	$	76,150		$	128,539		$	201,026		$	421,056
Reimbursement of Regeneron commercialization-related expenses	103,666			90,339			292,756			251,002
Regeneron's share of losses in connection with commercialization of antibodies	(38,924		)	(98,315		)	(182,595		)	(328,998		)
Other	33,166			41,848			82,150			84,338
Total Antibody	174,058			162,411			393,337			427,398
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	74,797			61,649			225,675			188,408
Reimbursement of Regeneron commercialization-related expenses	3,236			1,115			6,507			1,864
Other	4,174			20,000			57,989			60,000
Total Immuno-oncology	82,207			82,764			290,171			250,272
	$	256,265		$	245,175		$	683,508		$	677,670

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which are described below):



	Three Months Ended September 30,				Nine Months Ended September 30,
Bayer EYLEA Collaboration Revenue	2018		2017		2018		2017
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	243,152	$	205,367	$	721,522	$	571,126
Reimbursement of Regeneron EYLEA development expenses	1,676		6,053		8,811		10,833
Other	20,764		15,714		45,321		36,910
	$	265,592	$	227,134	$	775,654	$	618,869

Schedule of accounts receivable and deferred revenue information

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's IO Collaboration with Sanofi:



	September 30,		December 31,
	2018		2017
Accounts receivable	$	75,627	$	59,274
Deferred revenue	$	468,484	$	440,000

Significant changes in deferred revenue balances are as follows:



	Nine Months Ended September 30, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	93,643
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(65,159	)

The following tables summarize accounts receivable and deferred revenue information in connection with the Teva Collaboration Agreement:



	September 30,		December 31,
	2018		2017
Accounts receivable (recorded within Prepaid expenses and other current assets)	$	87,985	$	71,297
Deferred revenue	$	213,660	$	197,357

Significant changes in deferred revenue balances are as follows:



	Nine Months Ended September 30, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	48,216
Increase due to amounts invoiced, excluding amounts recognized as revenue during the period	$	33,774
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(67,771	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's EYLEA collaboration with Bayer:



	September 30,		December 31,
	2018		2017
Accounts receivable	$	269,155	$	241,153
Deferred revenue	$	85,504	$	68,734

Significant changes in deferred revenue balances are as follows:



	Nine Months Ended September 30, 2018
Increase due to shipments of commercial supplies to Bayer	$	47,958
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(31,188	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's Antibody Collaboration with Sanofi:



	September 30,		December 31,
	2018		2017
Accounts receivable	$	187,704	$	121,001
Deferred revenue	$	199,523	$	117,682

Significant changes in deferred revenue balances are as follows:



	Nine Months Ended September 30, 2018
Increase due to shipments of commercial supplies to Sanofi	$	178,608
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(96,767	)